Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clotiapine is an atypical antipsychotic belonging to the dibenzothiazepine chemical class, originally developed by Wander AG (later part of Novartis). It is primarily utilized in the treatment of schizophrenia and acute psychotic disorders, particularly in cases that are resistant to other treatments or require rapid tranquilization. The drug's pharmacological profile is characterized by its broad-spectrum antagonism of multiple G-protein coupled receptors, including potent activity at dopamine D2 and serotonin 5-HT2A receptors. It also exhibits significant affinity for histamine H1, alpha-1 adrenergic, and muscarinic acetylcholine receptors, which contributes to its pronounced sedative and anxiolytic effects. Clotiapine is available in both oral and parenteral formulations, making it a versatile option in emergency psychiatry for managing acute agitation and severe psychosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clotiapine.